Epic Code LAB1231688 Acetylcholine Receptor Modulating Antibody
Test Name Alias
ACHRMOD | XARMO | Acetylcholine Modulating Ab
Ordering Instructions
Assessment of clinical activity of and initial diagnostic testing for myasthenia gravis. For reflexive panel, which contains binding, blocking, and modulating antibodies, refer to Acetylcholine Receptor Antibody Reflexive Panel
Collection Instructions
Specimen Collection: Blood
Container(s): Gold Top Serum Separator Tube (SST)
Preferred Volume to Collect: 5 mL
Minimum Volume to Collect: 1.0 mL
Collection Instructions:
- Gold/Serum: Allow blood to clot for 30 minutes in a vertical position and centrifuge within 2 hours.
PROCESSING INSTRUCTIONS
Separate from cells ASAP or within 2 hours of collection.
Transfer 0.5 mL serum to an ARUP Standard Transport Tube. (Min: 0.3 mL)
Specimen Transport Temperature
REFRIGERATED
Rejection Criteria
- Contaminated
- Hemolyzed
- Severely lipemic
Specimen Stability
After separation from cells
Ambient: 48 hours
Refrigerate: 2 weeks
Frozen: 1 year (avoid repeated freeze/thaw cycles)
Test Frequency
Available Sun-Fri reported in 2-7 days after receipt at ARUP Lab
Reference Range
Components: Acetylcholine Modulating Antibody
Reference Interval: 45 or less modulating
Interpretive Data
Approximately 85-90 percent of patients with myasthenia gravis (MG) express antibodies to the acetylcholine receptor (AChR), which can be divided into binding, blocking, and modulating antibodies. Binding antibody can activate complement and lead to loss of AChR. Blocking antibody may impair binding of acetylcholine to the receptor, leading to poor muscle contraction. Modulating antibody causes receptor endocytosis resulting in loss of AChR expression, which correlates most closely with clinical severity of disease. Approximately 10-15 percent of individuals with confirmed myasthenia gravis have no measurable binding, blocking, or modulating antibodies.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Component | Interpretation |
---|---|
Acetylcholine Receptor Modulating Antibody | Negative: 0-45% modulating Positive: 46% or greater modulating |
Performing Department
Send out to ARUP Ref. Lab
Performing Department Laboratory Location
REFERRAL SEND OUTS
Methodology
Semi-Quantitative Flow Cytometry
CPT
86043
CDM Code
3028604302
Epic Test ID
123010353
LOINC
30192-9
Reviewed Date
4/2/2025 - Added to catalog